文献速递肿瘤 PET/CT

68Ga-PSMA-11与18F-PSMA-1007 PET/CT在前列腺癌分期中的头对头比较:以病理和免疫组化为参考标准

Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard.
PubMed 文献 · J Nucl Med · 2019-09-27

本研究在同一组16例新诊断中高危前列腺癌患者中,比较18F-PSMA-1007与68Ga-PSMA-11 PET/CT的诊断准确性,以根治性前列腺切除病理为参考标准。两种示踪剂对前列腺内病灶检测一致性几乎完美(κ 0.871–1),均识别所有优势前列腺内病灶;18F-PSMA-1007额外检测到4例患者的次要低强度病灶,其中3例为Gleason 3级、1例为慢性前列腺炎。

要点

  • 两种PSMA示踪剂在前列腺内病灶检测上一致性几乎完美(κ 0.871–1)。
  • 18F-PSMA-1007可额外检出低级别次要病灶,但临床相关性有限。
  • 本研究为试点研究,样本量16例,结论需进一步验证。

核心结论

  • 在中高危前列腺癌分期中,18F-PSMA-1007与68Ga-PSMA-11均能识别所有优势前列腺内病灶。
  • 18F-PSMA-1007可能检测到额外的低级别、临床相关性有限的病灶。

研究设计与样本

  • 试点研究,纳入16例新诊断中高危前列腺癌患者。
  • 患者均在15天内接受18F-PSMA-1007与68Ga-PSMA-11 PET/CT检查,并以根治性前列腺切除病理标本为参考标准。

主要发现

  • 16例患者前列腺内均检出PSMA阳性病灶,两种示踪剂一致性几乎完美(κ 0.871–1)。
  • 除双方均检出的优势前列腺内病灶外,18F-PSMA-1007在4例患者中额外检出次要低强度阳性灶。
  • 额外检出的4个次要灶中,3个病理证实为Gleason 3级病灶,1个为慢性前列腺炎。

关键数值与推荐

  • 采用Cohen κ系数评估两种示踪剂检测前列腺内病灶的一致性,κ范围为0.871–1。
  • 采用McNemar检验评估前列腺内PET/CT结果与组织病理结果的一致性。
  • 对每个示踪剂报告敏感度、特异度、阳性预测值和阴性预测值。
  • 测量所有病灶的SUVmax并计算肿瘤/本底活性比,采用Youden指数计算区分病变与非病变前列腺段的最佳SUV截断值。

临床怎么用

  • 两种PSMA示踪剂均可用于中高危前列腺癌分期中优势前列腺内病灶的识别。
  • 18F-PSMA-1007额外检出的低级别病灶需结合临床判断,避免过度解读。

局限性

  • 本研究为试点研究,样本量仅16例。
  • 文中未报告敏感度、特异度、阳性预测值、阴性预测值及最佳SUV截断值等具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18F-PSMA-1007 is a novel prostate-specific membrane antigen (PSMA)-based radiopharmaceutical for imaging prostate cancer (PCa). The aim of this study was to compare the diagnostic accuracy of 18F-PSMA-1007 with 68Ga-PSMA-11 PET/CT in the same patients presenting with newly diagnosed intermediate- or high-risk PCa. Methods: Sixteen patients with intermediate- or high-risk PCa underwent 18F-PSMA-1007 and 68Ga-PSMA-11 PET/CT within 15 d. PET findings were compared between the 2 radiotracers and with reference-standard pathologic specimens obtained from radical prostatectomy. The Cohen κ-coefficient was used to assess the concordance between 18F-PSMA-1007 and 68Ga-PSMA-11 for detection of intraprostatic lesions. The McNemar test was used to assess agreement between intraprostatic PET/CT findings and histopathologic findings. Sensitivity, specificity, positive predictive value, and negative predictive value were reported for each radiotracer. SUVmax was measured for all lesions, and tumor-to-background activity was calculated. Areas under receiver-operating-characteristic curves were calculated for discriminating diseased from nondiseased prostate segments, and optimal SUV cutoffs were calculated using the Youden index for each radiotracer. Results: PSMA-avid lesions in the prostate were identified in all 16 patients with an almost perfect concordance between the 2 tracers (κ ranged from 0.871 to 1). Aside from the dominant intraprostatic lesion, similarly detected by both radiotracers, a second less intense positive focus was detected in 4 patients only with 18F-PSMA-1007. Three of these secondary foci were confirmed as Gleason grade 3 lesions, whereas the fourth was shown on pathologic examination to represent chronic prostatitis. Conclusion: This pilot study showed that both 18F-PSMA-1007 and 68Ga-PSMA-11 identify all dominant prostatic lesions in patients with intermediate- or high-risk PCa at staging. 18F-PSMA-1007, however, may detect additional low-grade lesions of limited clinical relevance.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kuten J, Fahoum I, Savin Z, et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med. 2019. PMID: 31562225. doi:10.2967/jnumed.119.234187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。